Galapagos NV receives FDA clearance for Phase 1/2 ATALANTA-1 study of CD19 CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma.

Galapagos NV has received FDA clearance for its IND application for the Phase 1/2 ATALANTA-1 study of CD19 CAR-T therapy, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma. The study aims to evaluate safety, efficacy, and feasibility, using Galapagos' innovative decentralized platform, which could speed up and scale up therapy delivery. The Phase 1/2 study is currently ongoing in Europe, with early data showing encouraging results.

August 23, 2024
5 Articles